机译:通过exvivo活化和Ibrutinib改善CLL Vγ9VDelta 2-T细胞适用于细胞疗法
Univ Amsterdam Dept Hematol Amsterdam Infect &
Immun Inst Canc Ctr Amsterdam Amsterdam UMC;
Univ Amsterdam Dept Hematol Amsterdam Infect &
Immun Inst Canc Ctr Amsterdam Amsterdam UMC;
Vrije Univ Amsterdam Dept Med Oncol Canc Ctr Amsterdam Amsterdam Infect &
Immun Inst Amsterdam;
Univ Amsterdam Dept Hematol Amsterdam Infect &
Immun Inst Canc Ctr Amsterdam Amsterdam UMC;
Univ Amsterdam Dept Clin Epidemiol Biostat &
Bioinformat Amsterdam UMC Amsterdam Netherlands;
Univ Amsterdam Dept Clin Epidemiol Biostat &
Bioinformat Amsterdam UMC Amsterdam Netherlands;
Vrije Univ Amsterdam Dept Med Oncol Canc Ctr Amsterdam Amsterdam Infect &
Immun Inst Amsterdam;
Univ Amsterdam Dept Expt Immunol Amsterdam Infect &
Immun Inst Canc Ctr Amsterdam Amsterdam UMC;
Univ Amsterdam Renal Transplant Unit Amsterdam UMC Amsterdam Netherlands;
Leiden Univ Leiden Inst Chem Dept Mol Physiol Leiden Netherlands;
Leiden Univ Leiden Inst Chem Dept Mol Physiol Leiden Netherlands;
Rode Kruis Hosp Internal Med Beverwijk Netherlands;
Albert Schweitzer Hosp Dept Internal Med Dordrecht Netherlands;
Univ Amsterdam Dept Expt Immunol Amsterdam Infect &
Immun Inst Canc Ctr Amsterdam Amsterdam UMC;
Univ Amsterdam Dept Hematol Amsterdam Infect &
Immun Inst Canc Ctr Amsterdam Amsterdam UMC;
Vrije Univ Amsterdam Dept Med Oncol Canc Ctr Amsterdam Amsterdam Infect &
Immun Inst Amsterdam;
Vrije Univ Amsterdam Dept Med Oncol Canc Ctr Amsterdam Amsterdam Infect &
Immun Inst Amsterdam;
Univ Amsterdam Dept Hematol Amsterdam Infect &
Immun Inst Canc Ctr Amsterdam Amsterdam UMC;
机译:通过前体内激活和Ibrutinib改善CLLVγ9VDelta 2-T细胞适用于细胞治疗(Vol 132,PG 2260,2018)
机译:预防Vγ9VDelta 2 T细胞活化由Vγ9Vdelta 2 TCR纳米谱(Vol 198,PG 308,2017)
机译:在ZR-89标记的Vγ9VDelta 2 T细胞的体内PET跟踪到小鼠异种移植乳腺肿瘤,用脂质体醛固酮酸克
机译:带有核乳剂的快速伽马射线成像可用于质子治疗中的体内剂量验证
机译:活化吡啶的Zincke开环反应在δ-三丁基锡烷基-α,β,γ,δ-不饱和醛的合成中以及卟啉霉素A和B的形式合成中以及在Echinopines A和B中的合成
机译:体内α/βT细胞与γ/δT细胞之间的串扰:在用单克隆抗体GL3进行γ/δT细胞调节后α/βT细胞反应的激活。
机译:De Weerdt I,Hofland T,Lameris R等人。通过exvivo活化和伊布勒替尼改善CLLVγ9Vδ2-T细胞的适应性。血液。 2018; 132(21):2260-2272。